title: Re: Layton et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
authors.forename: F
authors.initials: F
authors.lastname: Degner
authors.forename: E
authors.initials: E
authors.lastname: Lesaffre
authors.forename: H
authors.initials: H
authors.lastname: Zeidler
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D015982:Bias; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D000077239:Meloxicam; D013450:Sulfones; D013843:Thiazines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007783:Lactones; D013450:Sulfones; D013843:Thiazines; D013844:Thiazoles; C116926:rofecoxib; D000077239:Meloxicam